Clinical Trials for Pancreas Cancer

Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable/metastatic pancreatic adenocarcinoma are subtyped by PurIST: basal-like tumors receive bi-weekly gemcitabine/nab‑paclitaxel plus low‑dose erlotinib (EGFR TKI) with dose optimization, while classical tumors receive standard oxaliplatin-based triplet chemotherapy (FOLFIRINOX or NALIRIFOX). Eligible patients have ECOG 0–1, measurable disease, no prior systemic therapy for PDAC, and tissue available for PurIST testing.

ClinicalTrials.gov ID: NCT06483555

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Adults with previously treated locally advanced/metastatic pancreatic adenocarcinoma (post–gemcitabine/nab-paclitaxel or FOLFIRINOX; ECOG 0–2) receive oral azeliragon, a small‑molecule RAGE antagonist targeting inflammatory signaling (HMGB1/S100/AGEs), using a loading then maintenance dosing schedule in a dose‑escalation, single‑arm study. Key exclusions include ECOG >2, short life expectancy, strong CYP2C8 inhibitors, malabsorption, and significant comorbidities.

ClinicalTrials.gov ID: NCT05766748

A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm study for adults with well/moderately differentiated, metastatic, unresectable, somatostatin receptor–positive pancreatic NETs (ECOG 0–2) who are PRRT- and sunitinib-naïve, allowing prior SSA and up to one prior systemic therapy. Investigates combination of lutetium Lu 177 dotatate PRRT and sunitinib (multi–TKI targeting VEGFR/PDGFR) to define safety/MTD and assess preliminary efficacy.

ClinicalTrials.gov ID: NCT05687123

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with biopsy-proven locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–2, minimal prior therapy allowed) receive standard multiagent chemotherapy plus endoscopic ultrasound–guided radiofrequency ablation of the primary tumor and pembrolizumab, an anti–PD-1 antibody. Aims to test whether local ablation can enhance immune priming and systemic activity of PD-1 blockade alongside chemotherapy.

ClinicalTrials.gov ID: NCT06831136

Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination with Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with unresectable/metastatic pancreatic adenocarcinoma after 1 prior platinum-based regimen (progressed or intolerant), ECOG 0–1, and measurable disease receive ZN-c3 (oral WEE1 kinase inhibitor targeting G2/M checkpoint via CDK1/2) plus gemcitabine; prior WEE1 inhibitors and prior gemcitabine in the incurable setting are excluded, with mandatory baseline and on‑treatment biopsies. Regimen: ZN-c3 Days 1–5, 8–12, 15–19 and gemcitabine IV Days 1 and 8 of 21-day cycles.

ClinicalTrials.gov ID: NCT06015659

Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma (ECOG 0–1) refractory to at least one fluoropyrimidine- or gemcitabine-based regimen receive atezolizumab (anti–PD-L1) plus cabozantinib (oral multi–TKI targeting MET/VEGFR/AXL). Excludes prior PD-1/PD-L1/CTLA-4 or cabozantinib exposure and patients with active autoimmune disease, uncontrolled cardiovascular/bleeding risks, or significant infection.

ClinicalTrials.gov ID: NCT04820179

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with locally advanced or metastatic pancreatic, lung, breast, and colorectal cancers who have progressed after standard treatments and exhibit tumor uptake of [68Ga]Ga-NNS309. It evaluates the safety and preliminary activity of the investigational radioligand [177Lu]Lu-NNS309, which targets specific tumor markers, though its exact mechanism of action is undisclosed.

ClinicalTrials.gov ID: NCT06562192

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, including specific types like hepatocellular carcinoma and non-small cell lung cancer, who have exhausted standard treatments, and assesses the safety and clinical activity of Decoy20, a Toll-like receptor agonist immunotherapy, both alone and in combination with the PD-1 inhibitor tislelizumab.

ClinicalTrials.gov ID: NCT05651022

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors, especially those with DNA damage repair deficiencies or PTGR1 overexpression, who have progressed after standard therapies. Patients receive LP-184, a PTGR1-activated prodrug that induces DNA double-strand breaks, as monotherapy or in combination with spironolactone (for recurrent glioblastoma) or olaparib (for triple negative breast cancer).

ClinicalTrials.gov ID: NCT05933265